Navigation Links
Barr Pharmaceuticals, Inc. Executive Bios
Date:3/28/2008

increasing responsibility

with the Company.

* 2001 Promoted to Senior Vice President, Manufacturing and

Engineering.

* 2007 Promoted to Executive Vice President, Global Product Supply.

* Prior to joining Barr, Bogda served as Vice President Operations

and Facility General Manager at Copley Pharmaceutical Inc. where

he managed the consolidation and integration of Copley's

manufacturing plants after the company's acquisition by Teva

Pharmaceuticals USA.

* Bogda served on the Executive Management Committee at Copley

Pharmaceuticals.

-- Master of Science in Chemical Engineering from Rutgers University

College of Engineering.

-- Master of Business Administration from the Wharton School.

Timothy B. Sawyer

Executive Vice President,

Global Generic Sales and Marketing,

Barr Laboratories, Inc.

-- As Executive Vice President, Global Generic Sales and Marketing

Operations, Timothy Sawyer has responsibility for the Company's generic

commercial operations for Europe/Rest of World ("ROW") and the U.S.

-- Most recently served as Barr's Senior Vice President of European

Commercial Development, with responsibility in the European and ROW

markets for all sales and marketing activities, including coordinating

business development activities among the country managers to enhance

Barr's product portfolio and increase profitability throughout the

European/ROW markets.

-- Barr: 15 years

* Joined Barr in 1993 as Manager, Sales Administration.

* Promoted to the position of Associate Director New Business

Development in 1996.

* Promoted to Director of Sales Administration and New Business


'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
3. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
4. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
5. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
6. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
7. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
8. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
9. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
10. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
11. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... 02, 2015 , ... Chris Harrison of Harrison’s Footwear of Poulsbo announces the ... really,” says Chris. “We have a lot of repeat customers, and many of them ... for them—so we’ve given them the convenience of ordering from home.” , Harrison’s Footwear ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... Los Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... working to expand their fleet of truly superb luxury vehicles based on which of ... are pleased to announce the latest step forward in pursuit of this goal: a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and Mildred ... comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. Rutherford, ...
Breaking Medicine News(10 mins):Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3
... mass, but long-term effects on vitality unclear, scientists say ... experimental drug can restore the amounts of muscle-linked growth ... shows. , Those on the therapy also gained muscle ... no clear indication that this led to significant improvements ...
... percent versus third quarter last year ... 4:30 p.m. Eastern Time Today, IRVINE, Calif., Nov. 6 ... intravascular temperature,management (IVTM(TM)) therapies for critically ill patients, today reported,on ... and,nine months ended September 30, 2008., Revenue for the ...
... Company Delivers First Month of Positive Gross Profits ... Corporation,(Nasdaq: PODD ), the leader in patch pump ... results for the three,and nine months ended September 30, ... $10.1 million compared to,$3.8 million in the third quarter ...
... November 06, 2008 Down syndrome, the most ... 1-in-700 births in the United States. Additionally, nearly 80 ... birth. , The Centers for Disease Control (CDC), in ... meeting of experts to review the current knowledge of ...
... STEWARTVILLE, Minn., Nov. 6 Rochester Medical,Corporation (Nasdaq: ... and year ended September 30, 2008., The Company ... to $8,437,000 for the fourth quarter of last year. ... $.03 per diluted share,compared to $733,000 or $.06 per ...
... ... Expectations, DENVER, Nov. 6 Air Methods ... 2008.,Revenue increased 32% to $133.8 million from $101.5 million in the year-ago,quarter. ... million in the prior-year nine-month period., For the quarter, net income ...
Cached Medicine News:Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 2Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 3Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 5Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 6Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 7Health News:Insulet Reports Third Quarter 2008 Results 2Health News:Insulet Reports Third Quarter 2008 Results 3Health News:Insulet Reports Third Quarter 2008 Results 4Health News:Insulet Reports Third Quarter 2008 Results 5Health News:Insulet Reports Third Quarter 2008 Results 6Health News:Insulet Reports Third Quarter 2008 Results 7Health News:Insulet Reports Third Quarter 2008 Results 8Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 8Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 2Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 3Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 4Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 5Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 6Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 7
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ... "An Introduction to Medical Device Software: Regulations and ... conference to their offering. This ... regulations and requirements that apply to Medical Device ... real life examples and state-of- the-art practices identified ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... standby switch maintains power to the instrument without generating ... of 50 Hz separated by .75 s; repeats every ... Hz (2 pulses/s) , Tetanus: 50 Hz (50 ... pulses/2 s; repeats every 10 s , Output Current: ...
Medicine Products: